EUVIMEDEUVIMED entdecken
Crossref

Identifying predictors of glioma evolution from longitudinal sequencing

Quanhua Mu iD, Ruichao Chai iD, Bo Pang, Yingxi Yang iD, Hanjie Liu, Zheng Zhao iD, Zhaoshi Bao iD, Dong Song iD, Zhihan Zhu, Mengli Yan, Biaobin Jiang iD, Zongchao Mo und 17 weitere

Science Translational Medicine · 04.10.2023 · 15 (716)

DOI: 10.1126/scitranslmed.adh4181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 04.10.2023. Verfasst von Quanhua Mu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, Division of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of …. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A deletion at initial diagnosis preceded tumor necrosis and microvascular proliferation that occur at later stages of IDH-mutant glioma. Ki67 expression at diagnosis was positively correlated with acquiring hypermutation at recurrence in the IDH–wild-type glioma. In all glioma subtypes, MYC gain or MYC- target activation at diagnosis was associated with treatment-induced hypermutation at recurrence. To predict glioma evolution, we constructed CELLO2 (Cancer EvoLution for LOngitudinal data version 2), a machine learning model integrating features at diagnosis to forecast hypermutation and progression after treatment. CELLO2 successfully stratified patients into subgroups with distinct prognoses and identified a high-risk patient group featured by MYC gain with worse post-progression survival, from the low-grade IDH-mutant-noncodel subtype. We then performed chronic temozolomide-induction experiments in glioma cell lines and isogenic patient-derived gliomaspheres and demonstrated that MYC drives temozolomide resistance by promoting hypermutation. Mechanistically, we demonstrated that, by binding to open chromatin and transcriptionally active genomic regions, c-MYC increases the vulnerability of key mismatch repair genes to treatment-induced mutagenesis, thus triggering hypermutation. This study reveals early predictors of cancer evolution under therapy and provides a resource for precision oncology targeting cancer dynamics in diffuse gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaAdultHumansTemozolomideMutationPrecision MedicineNeoplasm Recurrence, Local

Substanzen

Temozolomide

Autor:innen und Institutionen

  • Department of Chemical and Biological Engineering, Division of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, SAR 999077, China.
  • SIAT-HKUST Joint Laboratory of Cell Evolution and Digital Health, Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen, Guangdong 518045, China.
  • Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.
  • Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
  • Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
  • Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Korea.

ORCID-Profile: Quanhua Mu, Ruichao Chai, Yingxi Yang, Zheng Zhao, Zhaoshi Bao, Dong Song, Biaobin Jiang, Jihong Tang, Jason K Sa, Hee Jin Cho, Yuzhou Chang, Kaitlin Hao Yi Chan, Danson Shek Chun Loi, Sindy Sing Ting Tam, Aden Ka Yin Chan, Angela Ruohao Wu, Zhaoqi Liu, Wai Sang Poon, Ho Keung Ng, Danny Tat Ming Chan, Antonio Iavarone, Do-Hyun Nam, Tao Jiang, Jiguang Wang

Zitieren

APA

Mu, Q., Chai, R., Pang, B., Yang, Y., Liu, H., Zhao, Z., Bao, Z., Song, D., Zhu, Z., Yan, M., Jiang, B., Mo, Z., Tang, J., Sa, J. K., Cho, H. J., Chang, Y., Chan, K. H. Y., Loi, D. S. C., Tam, S. S. T., …, & Wang, J. (2023). Identifying predictors of glioma evolution from longitudinal sequencing. Science Translational Medicine, 15(716). https://doi.org/10.1126/scitranslmed.adh4181

Vancouver

Mu Q, Chai R, Pang B, Yang Y, Liu H, Zhao Z, et al. Identifying predictors of glioma evolution from longitudinal sequencing. Science Translational Medicine. 2023;15(716). doi:10.1126/scitranslmed.adh4181

BibTeX
@article{Mu2023,
  author = {Mu, Quanhua and Chai, Ruichao and Pang, Bo and Yang, Yingxi and Liu, Hanjie and Zhao, Zheng and Bao, Zhaoshi and Song, Dong and Zhu, Zhihan and Yan, Mengli and Jiang, Biaobin and Mo, Zongchao and Tang, Jihong and Sa, Jason K and Cho, Hee Jin and Chang, Yuzhou and Chan, Kaitlin Hao Yi and Loi, Danson Shek Chun and Tam, Sindy Sing Ting and Chan, Aden Ka Yin and Wu, Angela Ruohao and Liu, Zhaoqi and Poon, Wai Sang and Ng, Ho Keung and Chan, Danny Tat Ming and Iavarone, Antonio and Nam, Do-Hyun and Jiang, Tao and Wang, Jiguang},
  title = {Identifying predictors of glioma evolution from longitudinal sequencing},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {716},
  doi = {10.1126/scitranslmed.adh4181}
}
Kostenlos starten →